Skip to search formSkip to main contentSkip to account menu

1.7 ML denosumab 70 MG/ML Injection [Xgeva]

Known as: DENOSUMAB 120 mg in 1.7 mL SUBCUTANEOUS INJECTION [XGEVA], Xgeva 120 MG in 1.7 ML Injection, Xgeva 120 MG per 1.7 ML Injection 
National Institutes of Health

Related topics

Related topics

8 relations
InjectionSodium AcetateSorbitolWater

Broader (2)

Xgeva Injectable Productdenosumab Injection [Xgeva]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Osteonecrose mandibulaire sous denosumab et anastrozole
L’ostéonécrose des mâchoires (ONM) est une complication émergente de certains anticorps monoclonaux. Le cas présenté rapporte l… 
2013
2013
Jaký prospěch přináší denosumab (XGEVA®) pacientům s kostnímimetastázami solidních nádorů?
Mezi nadory casto metastazujici do kosti patři karcinom prostaty, ledviny a mocoveho měchýře. Doposud byly lekem volby u těchto… 
2012
2012
Blasenkrebs-Schnelltest liefert zuverlässige Ergebnisse
Solide Tumoren bilden Mediatoren, die Osteoklasten zur vermehrten Sekretion von RANKL (Receptor Activator of NF-κB-Ligand… 
2012
2012
Mit RANKL-Antikörper gegen Skelettmetastasen
Solide Tumoren bilden Mediatoren, die Osteoklasten zur vermehrten Sekretion von RANKL (Receptor Activator of NF-κB-Ligand… 
2011
2011
P4-13-01: Pain Severity and Analgesic Use Associated with Skeletal-Related Events in Patients with Advanced Breast Cancer and Bone Metastases.
Background: Skeletal-related events (SREs), which include pathologic fracture (PF), radiation to bone (RB), surgery to bone (SB… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)